Bulletin of Experimental Biology and Medicine

, Volume 125, Issue 1, pp 26–29 | Cite as

Effect of systemic administration of a new piracetam peptide analog on postresuscitation recovery of the central nervous system

  • I. V. Nazarenko
  • A. A. Kamenskii
  • T. A. Gudasheva
  • A. V. Volkov
General Pathology and Pathological Physiology
  • 19 Downloads

Abstract

Changes in the functions of the central nervous system were analyzed in albino rats resuscitated after a 12-min cardiac arrest. At the end of the first month after resuscitation, when the neurological status was completely restored, some emotional disturbances determining animal behavior were noted. Administration of GVS-111, a piracetam peptide analog, 30 min after the start of resuscitation increases survival rate, accelerates neurological recovery, and normalizes emotional reactivity in survivors.

Key Words

clinical death neurological status emotional reactivity nootropics peptides 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. Sh. Avrushchenko,Byull. Eksp. Biol. Med.,114, No. 8, 176–79 (1992).Google Scholar
  2. 2.
    G. V. Alekseeva,Anest. Reanimatol. No. 3, 70–71 (1980)Google Scholar
  3. 3.
    T. A. Gudasheva, G. G. Rozanov, R. U. Ostrovskayaet al., Khim.Farm. Zh.,29, No. 1, 15–18 (1995).Google Scholar
  4. 4.
    A. M. Gurvich, E. A. Mutuskina, and Yu. V. Zarzhetskii,Anest. Reanimatiol., No. 5, 6–9 (1994).Google Scholar
  5. 5.
    V. G. Korpachev, S. P. Lysenkov, and L. Z. Tel',Pat. Fiziol., No. 3, 78–80 (1982).Google Scholar
  6. 6.
    V. G. Korpachev, S. P. Lysenkov, and L. Z. Tel', in:Clinical Picture, Pathogenesis, and Management of Emergent States [in Russian], Novosibirsk (1982), pp. 8–13.Google Scholar
  7. 7.
    A. S. Maklakova, I. V. Nazarenko, V. A. Dubynin, et al.,Zh. Vyssh. Nervn. Deyat.,45, No. 6, 1143–1150 (1995).Google Scholar
  8. 8.
    V. A. Negovskii, A. M. Gyrvich, and E. S. Zolotokrylina,Postresuscitation Disease [in Russian], Moscow (1987).Google Scholar
  9. 9.
    R. U. Ostrovskaya and T. A. Gudasheva,Byull. Eksp. Biol. Med.,111, No. 5, 644–647 (1991).CrossRefGoogle Scholar
  10. 10.
    R. U. Ostrovskaya, T. A. Gudasheva, S. S. Trofimov,et al.,in: Pharmacology of Nootropics (in Russian), Moscow (1989), pp. 26–35.Google Scholar
  11. 11.
    D. W. Choi,J. Neurobiol.,23, 1261–1276 (1992).PubMedCrossRefGoogle Scholar
  12. 12.
    H. Hara, T. Sukamoto, and K. Kogure,Prog. Neurobiol.,40, 645–670 (1993).PubMedCrossRefGoogle Scholar
  13. 13.
    R. U. Ostrovskaya, T. A. Gudasheva, S. S. Trofimov,et al., Biological Basis of Individual Sensitivity of Psychtropic Drugs. Eds. S. B. Seredeninet al., Edinburgh (1995), pp. 79–91.Google Scholar
  14. 14.
    P. Safar,Ann. Emerg. Med.,22, Pt. 2, 324–327 (1993).PubMedCrossRefGoogle Scholar
  15. 15.
    S. B. Seredenin, T. A. Voronina, T. A. Gudasheva,et al., U.S. Patent No. 5,439,930, August 8, 1995, New York (1995).Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • I. V. Nazarenko
    • 1
    • 2
    • 3
  • A. A. Kamenskii
    • 1
    • 2
    • 3
  • T. A. Gudasheva
    • 1
    • 2
    • 3
  • A. V. Volkov
    • 1
    • 2
    • 3
  1. 1.Institute of General ResuscitationRussian Academy of Medical SciencesMoscow
  2. 2.M. V. Lomonosov Moscow State UniversityMoscow
  3. 3.Institute of PharmacologyRussian Academy of Medical SciencesMoscow

Personalised recommendations